Engineered antibody approaches for Alzheimer’s disease immunotherapy
Authors:
- Remy RobertRRRemy Robert
- Kim L. WarkKWKim L. Wark
- 1 October 2012
- journal article
- review article
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 526 (2) , 132-138
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Alzheimer's disease: strategies for disease modificationNature Reviews Drug Discovery, 2010
- Amyloid-β Immunotherapy for Alzheimers DiseaseCNS & Neurological Disorders - Drug Targets, 2010
- Forecasting the global burden of Alzheimer's diseaseAlzheimer's & Dementia, 2007
- Treatment Guidelines for Alzheimer's DiseaseThe Primary Care Companion For CNS Disorders, 2007
- Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A amyloid pathwayBrain, 2006
- Fine structure study of Aβ 1–42 fibrillogenesis with atomic force microscopyThe FASEB Journal, 2005
- Translating cell biology into therapeutic advances in Alzheimer's diseaseNature, 1999
- Disaggregation of Alzheimer β-amyloid by site-directed mAbProceedings of the National Academy of Sciences, 1997
- Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.Proceedings of the National Academy of Sciences, 1996
- The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptorNature, 1987